Physician profile
Paul R Hillman
NPI 1124405311
$68,415.80
in general payments reported to CMS, 2019-2025
10 companies · $64K in 2025
The $64K reported for 2025 was more than what 96% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $98.00 · 2021: $2,125 · 2022: $232 · 2023: $610 · 2024: $1,494 · 2025: $64K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $36K · Travel and Lodging: $15K · Honoraria: $10K · Food and Beverage: $3,275 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $610 · Education: $486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $36,245.00 |
| Travel and Lodging | $15,251.02 |
| Honoraria | $10,094.00 |
| Food and Beverage | $3,275.39 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $610.00 |
| Education | $485.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $49,407.21 | 2024-2025 | Cholbam, Ctexli, Livmarli |
| Chiesi USA, INC. | $10,058.59 | 2021-2025 | Elfabrio, Lamzede |
| Amicus Therapeutics, INC. | $3,679.27 | 2024-2025 | Pombiliti, Opfolda |
| Zevra Therapeutics INC | $3,449.54 | 2025 | Olpruva |
| Genzyme Corporation | $971.57 | 2023-2025 | |
| Biomarin Pharmaceutical INC. | $567.23 | 2020-2025 | Palynziq, Brineura |
| Ultragenyx Pharmaceutical INC. | $139.70 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.84 | 2025 | Elaprase |
| Cycle Pharmaceuticals INC | $57.81 | 2024 | Javygtor |
| Alexion Pharmaceuticals, INC. | $18.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Hillman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.